| Prostate-specific antigen following prostate radiotherapy: how low can you go? |
| PW McLaughlin, HM Sandler, and MR Jiroutek |
|
JCO Nov 1 1996: 2889–2892.
[PDF]
|
 |
|
Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer |
| |
FA Critz, AK Levinson, WH Williams, and DA Holladay |
| |
JCO Nov 1 1996: 2893–2900.
[Abstract]
[PDF]
|
|
|
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group |
| |
CM Coppin, MK Gospodarowicz, K James, IF Tannock, B Zee, J Carson, J Pater, and LD Sullivan |
| |
JCO Nov 1 1996: 2901–2907.
[Abstract]
[PDF]
|
|
|
Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study |
| |
C Balmaceda, G Heller, M Rosenblum, B Diez, JG Villablanca, S Kellie, P Maher, V Vlamis, RW Walker, S Leibel, and JL Finlay |
| |
JCO Nov 1 1996: 2908–2915.
[Abstract]
[PDF]
|
|
|
Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy |
| |
NW Lemmers, ME Gels, DT Sleijfer, JT Plukker, WT van der Graaf, ZJ de Langen, JH Droste, HS Koops, and HJ Hoekstra |
| |
JCO Nov 1 1996: 2916–2922.
[Abstract]
[PDF]
|
|
|
Evaluation of long-term toxicity after chemotherapy for testicular cancer |
| |
C Bokemeyer, CC Berger, MA Kuczyk, and HJ Schmoll |
| |
JCO Nov 1 1996: 2923–2932.
[Abstract]
[PDF]
|
|
|
Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma |
| |
NN Sharda, TJ Kinsella, and MA Ritter |
| |
JCO Nov 1 1996: 2933–2939.
[Abstract]
[PDF]
|
|
|
Geographic variation in the conduct of patient surveillance after lung cancer surgery |
| |
FE Johnson, KS Naunheim, MA Coplin, and KS Virgo |
| |
JCO Nov 1 1996: 2940–2949.
[Abstract]
[PDF]
|
|
|
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer |
| |
F Bertheault-Cvitkovic, A Jami, M Ithzaki, PD Brummer, S Brienza, R Adam, F Kunstlinger, H Bismuth, JL Misset, and F Levi |
| |
JCO Nov 1 1996: 2950–2958.
[Abstract]
[PDF]
|
|
|
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors |
| |
LB Saltz, J Kanowitz, NE Kemeny, L Schaaf, D Spriggs, BA Staton, R Berkery, C Steger, M Eng, A Dietz, P Locker, and DP Kelsen |
| |
JCO Nov 1 1996: 2959–2967.
[Abstract]
[PDF]
|
|
|
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma |
| |
FY Ahmed, E Wiltshaw, RP A'Hern, B Nicol, J Shepherd, P Blake, C Fisher, and ME Gore |
| |
JCO Nov 1 1996: 2968–2975.
[Abstract]
[PDF]
|
|
|
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer |
| |
SE Jones, MW Schottstaedt, LA Duncan, RL Kirby, RH Good, RG Mennel, TK George, DA Snyder, DL Watkins, CA Denham, FA Hoyes, and AS Rubin |
| |
JCO Nov 1 1996: 2976–2983.
[Abstract]
[PDF]
|
|
|
Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin |
| |
LJ Ayash, A Elias, G Schwartz, C Wheeler, J Ibrahim, BA Teicher, E Reich, D Warren, C Lynch, P Richardson, L Schnipper, E Frei, 3rd, and K Antman |
| |
JCO Nov 1 1996: 2984–2992.
[Abstract]
[PDF]
|
|
|
Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer |
| |
BA Leone, CT Vallejo, AO Romero, JE Perez, MA Cuevas, JA Lacava, CL Sabatini, ME Dominguez, R Rodriguez, MR Barbieri, EH Ortiz, MA Salvadori, LA Acuna, JM Acuna, MJ Langhi, S Amato, and MR Machiavelli |
| |
JCO Nov 1 1996: 2993–2999.
[Abstract]
[PDF]
|
|
|
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 |
| |
GL Rosner, JB Hargis, DR Hollis, DR Budman, RB Weiss, IC Henderson, and RL Schilsky |
| |
JCO Nov 1 1996: 3000–3008.
[Abstract]
[PDF]
|
|
|
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials |
| |
KS Albain, SR Green, AS Lichter, LF Hutchins, WC Wood, IC Henderson, JN Ingle, J O'Sullivan, CK Osborne, and S Martino |
| |
JCO Nov 1 1996: 3009–3017.
[Abstract]
[PDF]
|
|
|
Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin- 3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma |
| |
RM Lemoli, G Rosti, G Visani, F Gherlinzoni, MC Miggiano, A Fortuna, P Zinzani, and S Tura |
| |
JCO Nov 1 1996: 3018–3025.
[Abstract]
[PDF]
|
|
|
Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma |
| |
JA Sparano, PH Wiernik, X Hu, C Sarta, EL Schwartz, R Soeiro, DH Henry, B Mason, H Ratech, and JP Dutcher |
| |
JCO Nov 1 1996: 3026–3035.
[Abstract]
[PDF]
|
|
|
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies |
| |
K van Besien, D Przepiorka, R Mehra, S Giralt, I Khouri, J Gajewski, B Andersson, and R Champlin |
| |
JCO Nov 1 1996: 3036–3042.
[Abstract]
[PDF]
|
|
|
Low cholesterol and cancer |
| |
H Kritz, C Zielinski, and H Sinzinger |
| |
JCO Nov 1 1996: 3043–3048.
[Abstract]
[PDF]
|
|
| Therapy of primary systemic CD30-positive anaplastic large-cell lymphoma of the adult |
| R Fanin and F Silvestri |
|
JCO Nov 1 1996: 3049–3050.
[PDF]
|
|
| Clonality of Epstein-Barr virus in lymphoproliferative disorders in patients treated with immunosuppressive therapy for rheumatoid arthritis |
| M van de Rijn and OW Kamel |
|
JCO Nov 1 1996: 3050–3051.
[PDF]
|
|
